| 前收市價 | 36.11 |
| 開市 | 35.38 |
| 買盤 | 39.60 |
| 賣出價 | 44.40 |
| 拍板 | 120.00 |
| 到期日 | 2026-01-16 |
| 今日波幅 | 35.38 - 36.32 |
| 合同範圍 | 無 |
| 成交量 | |
| 未平倉合約 | 188 |
InvestorPlace3 Biotech Stocks With the Potential to Make You an Overnight Millionaire
Biotechnology offers breakthrough drugs and treatments that open new doors in the field of medicine. Companies are releasing more drugs and developing state-of-the-art methods to treat previously untreatable conditions. And their stocks show potential to soar upon Food and Drug Administration (FDA) approval and public market release. This excellent opportunity that biotech stocks present can provide investors with potentially exponential returns. Let’s learn about these three biotech stocks and
ZacksSarepta (SRPT) Q1 Earnings Beat Estimates, Revenues Up Y/Y
Sarepta (SRPT) reports better-than-expected Q1 earnings on the back of strong sales for recently-approved DMD gene therapy Elevidys.
Insider MonkeySarepta Therapeutics, Inc. (NASDAQ:SRPT) Q1 2024 Earnings Call Transcript
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Q1 2024 Earnings Call Transcript May 1, 2024 Sarepta Therapeutics, Inc. beats earnings expectations. Reported EPS is $0.37, expectations were $-0.11. Sarepta Therapeutics, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good afternoon and welcome […]
